Thus, our main goal here was to better understand the interplay between these two proteins, and how SLC26A9 might be used to develop novel CF therapies to be applied on their own or in combination with those currently available to further enhance their effects. The gene discussed is SLC26A9; the disease is cystic fibrosis.